<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01075555</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000666232</org_study_id>
    <secondary_id>FFCD-PRODIGE-11</secondary_id>
    <secondary_id>FFCD-0803</secondary_id>
    <secondary_id>EUDRACT-2009-015785-64</secondary_id>
    <secondary_id>EU-21005</secondary_id>
    <nct_id>NCT01075555</nct_id>
  </id_info>
  <brief_title>Sorafenib Tosylate With or Without Pravastatin in Treating Patients With Liver Cancer and Cirrhosis</brief_title>
  <official_title>Randomized Phase III Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federation Francophone de Cancerologie Digestive</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federation Francophone de Cancerologie Digestive</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Sorafenib tosylate and pravastatin may stop the growth of tumor cells by blocking
      some of the enzymes needed for cell growth. Sorafenib tosylate may also stop the growth of
      liver cancer by blocking blood flow to the tumor. It is not yet known whether sorafenib
      tosylate is more effective when given alone or together with pravastatin in treating patients
      with liver cancer and cirrhosis.

      PURPOSE: This randomized phase III trial is studying sorafenib tosylate given together with
      pravastatin to see how well it works compared with giving sorafenib tosylate alone in
      treating patients with liver cancer and cirrhosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To evaluate the effects of sorafenib tosylate and pravastatin versus sorafenib tosylate
           alone on overall survival of patients with hepatocellular carcinoma and Child-Pugh Class
           A cirrhosis.

      Secondary

        -  To evaluate the effect of this regimen on progression-free survival, time to
           progression, time to treatment failure, and quality of life (QLQ-C30 and FACT hep) in
           these patients.

        -  To evaluate the benefit of on-site monitoring versus the centralized data management
           monitoring of these patients.

        -  To characterize polymorphisms to specify the haplotype diversity in these patients.

        -  To test both diagnostic and prognostic signatures by quantitative RT-PCR to determine if
           they can predict response to these regimens.

      OUTLINE: This is a multicenter study. Patients are stratified according to participating
      center, Cancer of the Liver Italian Program (CLIP) score (0 vs 1 vs 2-4), WHO performance
      status (0 vs 1 vs 2), portal vein thrombosis (presence vs absence), and extrahepatic
      metastases (presence vs absence). Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive oral sorafenib tosylate twice daily on days 1-28 and oral
           pravastatin once daily on days 1-28. Courses repeat every 4 weeks in the absence of
           disease progression or unacceptable toxicity.

        -  Arm II: Patients receive oral sorafenib tosylate twice daily on days 1-28. Courses
           repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

      Patients complete quality-of-life questionnaires (QLQ-C30 and FACT) at baseline and then
      every 4 weeks during and after completion of study therapy.

      Blood and tissue samples may be collected for laboratory analysis, including pharmacogenomic
      studies.

      After completion of study therapy, patients are followed up periodically.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2014</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2014</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>2014</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>2014</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">323</enrollment>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>sorafenib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sorafenib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sorafenib + pravastatine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sorafenib + pravastatine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pravastatin sodium</intervention_name>
    <arm_group_label>sorafenib + pravastatine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib tosylate</intervention_name>
    <arm_group_label>sorafenib</arm_group_label>
    <arm_group_label>sorafenib + pravastatine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of hepatocellular carcinoma (HCC), meeting 1 of the following criteria:

               -  Histologically confirmed HCC

               -  If histological proof can not be obtained (e.g., ascites, coagulation disorders),
                  the diagnosis may be made in cases of cirrhosis according to the 2005 EASL/AASLD
                  criteria by demonstration of a focal hepatic lesion &gt; 10 mm, meeting 1 of the
                  following criteria:

                    -  Hypervascular tumor &lt; 2 cm by 2 dynamic-imaging techniques (e.g., spiral CT
                       scan, MRI scan, or ultrasound with contrast medium)

                    -  Hypervascular tumor ≥ 2 cm by 1 dynamic-imaging technique (e.g., spiral CT
                       scan, MRI scan, or ultrasound with contrast medium)

          -  No progressive disease following prior treatment

          -  Not eligible for curative treatment (i.e., transplantation, resection, or percutaneous
             destruction) or chemoembolization

          -  Cancer of the Liver Italian Program (CLIP) prognosis score 0 to 4

          -  Child-Pugh score A

          -  No extrahepatic disease threatening the short- or medium-term vital prognosis

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0-2

          -  Life expectancy &gt; 12 weeks

          -  Transaminases ≤ 5 times upper limit of normal (ULN)

          -  Serum creatinine ≤ 1.5 times ULN

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception during and for 3 months after
             completion of study therapy

          -  No other cancerous pathology, except for carcinoma in situ of the cervix, superficial
             bladder tumors, treated basal cell carcinoma, or any other cancer treated curatively ≥
             3 years ago

          -  No cardiac insufficiency (NYHA class II or IV congestive heart failure), arterial
             hypertension, uncontrolled arrhythmia, or myocardial infarction within the past 6
             months

          -  No digestive hemorrhage within the past month

          -  No major bleeding disorder

        PRIOR CONCURRENT THERAPY:

          -  No prior or other concurrent statins

          -  No prior sorafenib tosylate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Louis Jouve</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Du Bocage</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacques Denis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Louise Michel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Du Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2010</study_first_submitted>
  <study_first_submitted_qc>February 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2010</study_first_posted>
  <last_update_submitted>May 26, 2016</last_update_submitted>
  <last_update_submitted_qc>May 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult primary hepatocellular carcinoma</keyword>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Pravastatin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

